P101: Oncotype DX testing provides valuable prognostic information for guiding adjuvant chemotherapeutic treatment of breast cancer patients with intermediate/high risk predict or NPI scores

Christopher Hillyar,Hirah Rizki,Omar Abbassi,Gill Clayton,Sascha Miles-Dua,Tasha Gandamihardja,Simon Smith

Ejso（2020）

Cited 0|Views7

No score

Abstract

Introduction: Risk calculators (PREDICT/NPI) estimate a patient's risk of breast cancer recurrence based on clinico-pathological features, whereas Oncotype DX (ODX) utilises genetic profiling. This study aimed to assess the correlation between the risk of recurrence estimated by PREDICT and NPI in comparison with ODX.

Translated text

Key words

Cancer Risk,cancer susceptibility,Breast Cancer

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined